- Home
- HSDT vs IMUX Comparison
HSDT vs IMUX Comparison
Compare HSDT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSDT | IMUX |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 21 | 66 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.6M | 75.2M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HSDT | IMUX |
|---|---|---|
| Price | $2.16 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 344.6K | ★ 3.1M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.51 |
| 52 Week High | $25.50 | $1.51 |
Technical Indicators
Market Signals| Indicator | HSDT | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | 58.93 |
| Support Level | $1.78 | $0.64 |
| Resistance Level | $2.37 | N/A |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 62.26 | 50.00 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.